Modular NeoVax Platform for Cancer Vaccine

From surgical treatment, radiation therapy, traditional chemotherapeutics to precision medicine to today's new force and hot immunotherapy, the challenge of cancer has been the focus of the medical and scientific research community. Creative Biolabs is a professional CRO that provides technical support and services to vaccine researchers. We have more than 10 years of case processing experience in the field of vaccines, always tracking the most cutting-edge research progresses and internalizing them into our unique technologies, and then externalizing into a series of reliable services is a distinctive feature that differentiates us from other competitors.

Background

Advances in early detection and diagnostic methods have improved the treatment of cancer and the survival rate of cancer patients to some extent, but more than half of the patients diagnosed with cancer still could not survive for more than 5 years. In the past, the commonly used surgical treatments, radiotherapy, and chemotherapy have a prolonged life expectancy, but they have serious side effects, and patients receiving these treatments often suffer as much as they suffer from cancers. In recent years, with the advancement in immunology, the researchers found that the immune system of tumor patients is often in an immunosuppressed state, and the body's own immune system is likely to be the magic weapon to finally defeat cancer. Therefore, re-waking up the body's immune function and developing immunotherapy against cancer cells will be a welcome and promising strategy. Vaccination is a proven immunotherapy that has a glorious record in the prevention of infectious diseases, and it is now showing great potential in the prevention and treatment of cancer.

Modular NeoVax Platform

Vaccine development utilizes the self-nonself discrimination mechanism of the immune system. Different from the infectious diseases causing pathogens, tumor cells derive from normal cells often do not express any differentiating molecular markers from normal cells. However, most tumor cells can express different types of tumor antigens, one is tumor-associated antigen with low expression level in normal tissues and high expression level in tumor tissues; the other is the tumor-specific neoantigen caused by tumor genome mutation, which is not present in normal tissues and thus avoids accidental injury to normal tissues. NeoVax takes advantage of this property of tumor neoantigens.

NeoVax modularly includes three main functional components: a targeting module, a dimerization module, and a tumor neoantigen module. The targeting module enables the vaccine to target and bind to antigen-presenting cells (APCs), which are then internalized into APCs and mediate the maturation of APCs to initiate immune responses. The benefit of this design is that it increases the efficiency of internalized neoantigens’ presentation to helper T cells and cytotoxic T cells and increases the intensity of the immune response. In addition, the modular form also makes it easier to design individualized vaccines and to modify them.

Highlight Features of NeoVax Platform

• Suitable for the development of infectious disease and cancer vaccines
• Can be used for preventive or therapeutic purposes
• Able to achieve the individualized design of vaccines
• Stimulate either or both B cell and T cell immunity
• Flexibility to design as DNA, RNA and protein vaccines

Creative Biolabs has a top-notch vaccine development team and our R&D staff has extensive experience in vaccine development. In addition to providing reliable services in routine vaccine development, we have designed a variety of advanced vaccine development platforms for our clients that will further assist our clients' research. If you have the need for vaccine development, we will be your best partner!

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.